Navigation Links
WuXi PharmaTech Celebrates Dr. Joseph Vacca's Induction into American Chemical Society's Medicinal Chemistry Hall of Fame
Date:9/4/2012

SHANGHAI, Sept. 4, 2012 /PRNewswire/ -- Dr. Joseph Vacca, Senior Vice President of the Early Success Sharing Partnerships (ESSP) business unit of WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading research and development outsourcing company serving the pharmaceutical, biotechnology, and medical device industries, was inducted into the Medicinal Chemistry Hall of Fame of the American Chemical Society (ACS), the world's largest scientific society with more than 164,000 members.  The induction was held in August 2012 during the 244th ACS National Meeting in Philadelphia.  Dr. Vacca was honored for his outstanding contributions to the discovery of novel therapeutics, including CRIXIVAN™, Isentress™, and many compounds in advanced clinical studies.

In the spirit of celebrating excellence, WuXi hosted a special luncheon to honor Dr. Vacca, attended by many colleagues, collaborators, and distinguished guests of WuXi's global network.  At the event, several leading chemists praised Dr. Vacca's accomplishments.

"Dr. Vacca sets the standard of leadership in the discipline of drug discovery," commented Dr. Paul Anderson, former Merck Chemistry Site Head, past ACS President, and winner of the ACS Priestley Medal.

"Advancing innovative science to effective therapies is an enormous challenge that requires strong partnership between academia and industry," added Dr. Chi-Huey Wong, the 2012 ACS Arthur C. Cope Award recipient, Ernest W. Hahn Professor of Chemistry at the Scripps Research Institute, and President of Academia Sinica.  "Expertise from veterans like Dr. Vacca will be vital to speed translation of discoveries into medicines for patients."

"We are particularly delighted that ACS has recognized Dr. Vacca's contributions to the chemical society and to industry through his leadership in the discovery of important, ground-breaking therapies," commented Dr. Ge Li, Chairman and CEO of WuXi PharmaTech.  "Today more than ever, our industry needs a strong collaborative ecosystem to improve R&D productivity for the benefit of our patients.  Dr. Vacca exemplifies WuXi's mission of providing the very finest industry expertise across our open-access platforms to enable anyone and any company to discover and develop drugs more efficiently and cost-effectively."

Dr. Vacca has had a distinguished career in medicinal chemistry and drug discovery.  Prior to working at WuXi, Dr. Vacca held positions within the Merck Research Laboratories Chemistry organization as Vice President of Chemistry at the Kenilworth, New Jersey, site and as the Global Head of Structural Chemistry.  He retired from Merck in November 2011.  Dr. Vacca is the author of more than 100 publications and patents and has received many awards, including the Merck Directors Award given by the Merck Board of Directors (1998); the Pharmaceutical Research and Manufacturers of America Discoverers Award (1999); the Intellectual Property Owners' National Inventor of the Year Award (1997); the European Patent Office's European Inventor of the Year for non-European inventors (2007); the ACS Award for Creative Invention (1999); and designation as a Merck Research Laboratories Presidential Fellow (2008).

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States.  As an innovation-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process.  WuXi PharmaTech's services are designed to assist its global partners in shortening the timeline and lowering the cost of drug and medical device R&D.  WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec.  For more information, please visit http://www.wuxiapptec.com or contact:

Aaron Shi
Assistant Director of Corporate Communications
Tel: +86-21-5046-4362
Email: Aaron_Shi@wuxiapptec.com

Ronald Aldridge
Director of Investor Relations
Tel: +1-201-585-2048
Email: Ron_Aldridge@wuxiapptec.com

 


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. WuXi PharmaTech and Open Monoclonal Technology Announce OmniRat(TM) Antibody Collaboration
2. WuXi PharmaTech to Manufacture Ibalizumab for TaiMed Biologics
3. WuXi PharmaTech Receives GLP Certificate from SFDA for Suzhou Toxicology Facility
4. WuXi PharmaTech Announces Second-Quarter 2012 Results
5. Pharmatech Oncology Receives Phase 2 SBIR Funding for Just-In-Time Enrollment Model
6. WuXi PharmaTech Announces First-Quarter 2012 Results
7. Industry Leading Pharmaceutical News Website in-Pharmatechnologist.com Refocused and Relaunched
8. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
9. Cardinal Health Celebrates Community Pharmacists Commitment to Patient Care at Annual Trade Show for Independent Pharmacies
10. Collagen Matrix Celebrates 15th Anniversary in the Medical Device Business
11. Leading Pension Annuity Provider Legal & General, Celebrates 175 Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... -- Research and Markets has announced the addition ... Analysis By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, ... report to their offering. ... The Latin American pharmaceutical contract manufacturing services market is ... Low drug registration cost in Latin American countries and continuous ...
(Date:4/19/2017)... YORK , April 19, 2017 Cardiology devices ... the projected period The Cardiology Devices segment is ... than US$ 15 Mn in 2018 over 2017. By the ... a market valuation close to US$ 700 Mn, expanding at ... Devices segment dominated the Asia Pacific ...
(Date:4/19/2017)... MOUNTAIN VIEW, Calif. , April 19, 2017 /PRNewswire/ ... that it will release financial results for the first ... May 3, 2017.  The Company,s management team will host ... / 5:30 p.m. ET. Investors interested in ... dialing (844) 707-0665 for domestic callers or (703) 326-3030 ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... Infertility may be ... conditions and has helped many women become pregnant upon treating their diagnosis. ... and simple outpatient evaluations. We can provide the necessary information to diagnose ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... domain expertise for sponsors and CROs to speed clinical development, has released ... software platform. Bioclinica AGILE RTSM provides seamless clinical supply forecasting ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... committed to raising awareness for Duchenne muscular dystrophy, and funding for Duchenne ... (cardiosphere-derived cells) Phase I/II HOPE clinical trial in Duchenne announced today. , ...
(Date:4/25/2017)... ... April 25, 2017 , ... Lake Park Dental is now ... Invisalign® in Lutz, FL. With the help of this highly-effective, yet convenient ... fewer potential complications, more discretion and less pain. , Drs. Sarah Jockin, Nicole ...
(Date:4/25/2017)... ... ... Buyers and sellers in the thriving multi-billion dollar cannabis marketplace – from medical ... heartened by the industry’s current surge. But another thing that unifies them is a ... last they can simply, safely and effectively end their aroma anguish thanks to a ...
Breaking Medicine News(10 mins):